Surrozen, Inc (SRZN): Price and Financial Metrics
GET POWR RATINGS... FREE!
SRZN Stock Price Chart Interactive Chart >
SRZN Price/Volume Stats
| Current price | $0.71 | 52-week high | $3.97 |
| Prev. close | $0.71 | 52-week low | $0.34 |
| Day low | $0.70 | Volume | 166,096 |
| Day high | $0.75 | Avg. volume | 742,485 |
| 50-day MA | $0.61 | Dividend yield | N/A |
| 200-day MA | $2.13 | Market Cap | 24.82M |
Surrozen, Inc (SRZN) Company Bio
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
Latest SRZN News From Around the Web
Below are the latest news stories about SURROZEN INC that investors may wish to consider to help them evaluate SRZN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateSOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter of 2022 and provided a corporate update. SZN-1326 UpdateSurrozen announced today that it voluntarily paused enrollment in the single ascending dose (SAD) portion of the Company’s Phase 1 clinical tria |
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) WeekSZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studiesSZN-1326 preclinical data shows improved intestinal epithelial healing, restored epithelial barrier, and reduced colitis-associated collagen deposition and was well tolerated in non-clinical toxicology studies SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering ta |
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal DiseasesThe collaboration and licensing agreement is Surrozen’s first strategic partnership for one of its compounds in developmentSurrozen's novel antibody-based approach targets Fzd4 biology, which has been shown to play a fundamental role in retinal vascular integrity and functionThe new partnership combines Surrozen’s proprietary SWAP™ technology for modulating Wnt signaling with Boehringer Ingelheim’s research and development expertise to develop a first-in-class treatment for patients with eye dis |
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic RetinopathyResults highlight a potential novel treatment for diabetic and other retinopathiesUnique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth into physiological regrowth of retinal blood vessels SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today the publication of an article by Surro |
SRZN Price Returns
| 1-mo | 22.01% |
| 3-mo | -65.87% |
| 6-mo | -76.25% |
| 1-year | -70.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 22.01% |
| 2022 | -90.96% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...